Expression of CD24 in preclinical mouse models has been shown to promote breast cancer metastasis by increasing both proliferation and adhesion.30 These results are timely given the fast paced development of cancer immunotherapy agents, as they suggest a role for such agents in early stage HR+ cancers in addition to HER2+ and TNBC. Here, ERBB2 is linked to breast cancer.